 Arcutis Biotherapeutics Inc NASDAQ: ARQT has obtained a 225 million term loan facility from SLR Capital Partners SLR. This additional capital further strengthens Arcutis balance sheet before a potential 2022 FDA approval launch of topical roflumilast cream in plaque psoriasis and three 2022 pivotal data readouts in skin disorder trials. 